BJMO - 2021, issue SPECIAL, march 2021
D.E. Spratt MD
Currently, the main prognostic biomarkers used in the management of prostate cancer are molecularly defined, including prostate specific antigen (PSA), Gleason score, D’Amico risk group, National Comprehensive Cancer Network (NCCN) risk groups, etc. More recently, genomic classifiers have been developed to facilitate a better precision medicine in patients with prostate cancer. During his lecture at the 2021 BMUC meeting, Dr. Daniel E. Spratt gave an overview of the current biomarker landscape in patients with prostate cancer and made a case for the use of these novel genomic classifiers.
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.